The therapeutic landscape of platinum-resistant ovarian cancer (PROC) is expanding rapidly with an influx of novel antibody-drug conjugates (ADCs) featuring distinct target antigens, cleavable linkers, and potent cytotoxic payloads. To translate novel therapies into personalized care, clinicians must keep up with the latest trial evidence, payload mechanics, and nuances across emerging ADC platforms. Join two expert ovarian cancer specialists for the second webinar in this 3-part series to dive deeper into the latest clinical data supporting ADCs targeting folate receptor alpha (FR ), HER2, CDH6, B7-H4, and other tumor-associated antigens in PROC. Featuring interactive polling, dynamic panel discussions, and a live Q&A, this session will examine key trial outcomes, analyze bystander activity, and contextualize emerging evidence for diverse patient populations. Take away critical insights to evaluate the growing body of evidence, differentiate therapeutic platforms, navigate patient selection, and advance ADC integration for patients with PROC.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
No specific specialties targeted.
Pricing
99% of listed courses are free
298 of a sample of 300 are free · 416 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Interventional Radiology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Musculoskeletal Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Neurology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1 credit
- Commercial Support
-
WhenDec 2–3, 2026
-
PRIME Education, Inc. (PRIME®) Decrypting ADC Targets in PROC: Biomarker Expression, Testing, and Clinical Interpretation
-
PRIME Education, Inc. (PRIME®) The Next Wave of ADC Innovation in Platinum-Resistant Ovarian Cancer
-
PRIME Education, Inc. (PRIME®) Expanding the ADC Arsenal in Platinum-Resistant Ovarian Cancer
-
Creative Educational Concepts, Inc. The FR Frontier: New Pathways in Platinum-Resistant Ovarian Cancer
-
Physicians’ Education Resource The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing
-
Clinical Care Options, LLC (dba Decera Clinical Education) InterACT ADC Treatment Optimization & Care Team Activation in PROC: Enhancing Multidisciplinary Implementation, Toxicity Mitigation, and Workflow Readiness in Community Practice
